Liquidia Corp. (LQDA)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-09
$69.12+2.13%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-09
Broken: Primary pillar broken — Full year 2026 revenue: FY26 rev $129.9M vs $130M target.
Liquidia is growing sales of YUTREPIA fast, from $54M to $133M in recent quarters. Net income improved from $15M to $53M, showing better profits. Cash from operations also rose, supporting growth. The company has strong patent news and market confidence.
Liquidia is still loss-making with a very high PE of 580. Sales guidance for 2026 is lower than 2025, signaling risk. Insider selling and past earnings misses raise concerns about execution and sustainability.
The price is about 14% above our fair value near $71, reflecting analysts' expectation of 100% revenue growth. Our fair value is slightly above the Street median, showing some optimism but also risk.
Breaks if: Cash from operations falls below $40M in any quarter after 2026-Q1
Enhance cash flow from operating activities to support financial stability and growth.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. LQDA is currently loss-making but has shown strong sales growth and management stability, making it a candidate for long-term growth despite near-term risks.
The market appears to price LQDA at an expensive valuation compared to peers, reflecting justified expectations for future growth. However, there is a notable expectations gap, indicating that the market may not fully account for potential volatility in earnings.
Management is focused on increasing sales of YUTREPIA and achieving profitability, with recent financial results showing mixed progress. The near-term risk is elevated, as the company has a significant probability of missing earnings expectations based on recent performance trends.
The thesis hinges on LQDA's ability to sustain sales growth and manage profitability while navigating potential headwinds from the broader economic environment. Additionally, the performance of sector peers will be critical in shaping market sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. Yutrepia sales growth continues to exceed expectations, reinforcing revenue targets. There are no new threats impacting the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 2 of last 2 quarters. Cash and cash equivalents increased from $222.8 million in 2026-Q1 to $284.2 million in 2026-Q2, with positive cash from operations of $52.99 million in 2026-Q1. The trajectory shows improvement in cash position consistent with management focus.
“Cash and cash equivalents increased to $284.2 million as of June 30, 2026.”
“Cash and cash equivalents increased to $222.8 million as of March 31, 2026.”
Breaks if: Net income falls below $30M in any quarter after 2026-Q1
Breaks if: Full year 2026 revenue falls below $120M
Continue growing net product sales of YUTREPIA inhalation powder and expand patient adoption since launch in June 2025.
Stated as a priority in 2 of last 2 quarters. YUTREPIA net product sales grew from approximately $130 million in 2026-Q1 to $170.4 million in 2026-Q2, a 31% increase. Patient prescriptions increased to about 5,900 since launch. The trajectory is delivering consistent growth in sales and adoption.
“YUTREPIA net product sales of approximately $170.4 million in Q2 2026, up 31% from Q1 2026.”
“YUTREPIA net product sales of approximately $130 million in Q1 2026.”
Breaks if: YUTREPIA sales fall below $100M in any quarter after 2026-Q1
Continue growing net product sales of YUTREPIA inhalation powder and expand patient adoption since launch in June 2025.
Stated as a priority in 2 of last 2 quarters. YUTREPIA net product sales grew from approximately $130 million in 2026-Q1 to $170.4 million in 2026-Q2, a 31% increase. Patient prescriptions increased to about 5,900 since launch. The trajectory is delivering consistent growth in sales and adoption.
“YUTREPIA net product sales of approximately $170.4 million in Q2 2026, up 31% from Q1 2026.”
“YUTREPIA net product sales of approximately $130 million in Q1 2026.”
Over the next 1 to 3 years, LQDA's trajectory will depend on its execution of key priorities and external market conditions. Not investment advice.